Findings from MOST Trial Presented at ISC24: Blood thinners added to clot-busting medication did not improve stroke outcomes
Researchers presenting preliminary late-breaking science presented on the first day of the American Stroke Association’s International Stroke Conference 2024 reported findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial. The results showed that giving blood thinners in addition to clot-busting medications to people with ischemic strokes (clot-caused strokes) did not improve their outcomes 90 days later.